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Summary: Technical improvements have been applied to reduce the time required for the determination of
calcidiol and calcitriol in serum or plasma. The modifications include the use of Sep-Pak CIS cartridges for
the extraction of calciol metabolites from serum instead of a classical liquid/liquid extraction, a considerable
shortening of the HPLC purification time compared with our previously described method, and the application
of HPLC with UV detection at 254 nm of calcidiol as an alternative to the usual competitive protein binding
methods. In none of the 199 samples where calcidiol was determined by HPLC did we observe a detectable
peak of ercalcidiol. Quantitation of calcidiol by HPLC and competitive protein binding assay was compared
in 5 series of assays. The correlation between the two methods was 0.99. The average slope of the linear
regression line when the HPLC values were plotted versus the competitive protein binding values was 1.14.
The average intercept was 0.19 nmol/1. The mean within-run coefficient of variation for calcidiol in these
series was 5% for the competitive protein binding method, and 4% for the HPLC method. Between-run
coefficients of variation were 6% and 12% for the competitive protein binding and for the HPLC method,
respectively. Within-run and between-run coefficients of variation for calcitriol were 6% and 15%, respectively.
Introduction
Methods for the determination of calciol metabolites
in plasma or serum have always been laborious due
to the necessity for extensive prepurification before
quantitation (1, 2). Determination of calcidiol by
HPLC with UV detection at 254 nm is possible only
after at least two Chromatographie procedures (3 — 5),
or after one Chromatographie prepurification and
conversion to a (5E)-(10S)-10,19-dihydrocalciol deriv-
ative (6). Quantitation of calcidiol by HPLC enables
the separate determination of ercalcidiol and calcidiol.
The competitive protein binding method, however,
gives only the sum of both compounds. Previously,
we described a procedure for the simultaneous deter-
mination of calcidiol, calcitriol and (24R)-hydroxy-
calcidiol (7). For large clinical research projects, where
hundreds of samples have to be analysed, and for
routine clinical use, it was desirable to develop a less
time consuming method, especially with respect to the
HPLC procedure used for the purification of the
sample extracts. Here we describe the technical details
of the modifications which resulted in a substantial
reduction of HPLC time required for prepurification
of the sample extracts. In addition, we describe a
modified sample extraction with Sep-Pak CIS car-
tridges and a comparison of the quantitation of cal-
cidiol by HPLC with UV detection at 254 nm and
competitive protein binding assay.
Materials and Methods
Materials
Nonradioactive calcidiol and calcitriol were obtained from Du-
phar BV, Weesp, The Netherlands and Hoffmann-LaRoche,
Basle, Switzerland, respectively. [27-methyl-3H]calcidiol (spec,
act. 185 — 555 GBq/mmol) and [23,24(n)-3H]calcitriol (spec. act.
2.6—4.1 TBq/mmol) were purchased from Amersham Nedcr-
land BV, Utrecht, The Netherlands. Calciol metabolites were
stored in absolute ethanol at -20°C. All solvents were of
commercially available analytical grade and were used without
further purification. Radioactivity in aqueous samples was
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counted in 10 ml of Instagel (Baker Chemicals, Deventer, The
Netherlands). Radioactivity in organic solvents was measured
in 5 ml of Permafluor III (Packard Instruments Benelux SA,
Brussels, Belgium) diluted ten-fold with toluene. Nucleosil
packing materials for HPLC columns were from Macherey &
Nagel, D ren, FRG.
Appara tus
The Altex HPLC system (Altex, Berkely, CA 94710) was essen-
tially the same as described before (7). A Rheodyne Model
7040A low dead volume valve fitted with a Model 7163 solenoid
valve (Rheodyne Inc, Ciotati, CA 94928) was added to the
system in order to enable reversal of the flow through the
HPLC column. Fractions were collected with an LKB Model
Ultrorac 7000 fraction collector (LKB, Bromma, Sweden). A
Sep-Pak cartridge rack (Millipore/Waters Ass., Etten Leur, The
Netherlands) was used for the processing of sample extracts
with Sep-Pak CIS cartridges. Radioactivity was measured in a
Philips Model PW 4700 liquid scintillation counter (Philips,
Almeio, The Netherlands).
Sample preparation
To 4 ml of plasma or serum were added approximately 83 Bq
each of tritiated caicidiol and calcitriol. After equilibration at
ambient temperature for 30 minutes, one volume of acetonitrile
was added to the sample. After vortex-mixing the denatured
proteins were pelleted by centrifugation. Subsequently, 0.6 vol-
ume of water was added to the supernatant, which was then
applied to a Sep-Pak C18 cartridge. The cartridge was washed
with 5 ml of methanol/water (60 + 40 by vol). Calciol metab-
olites were eluted with 2.5 ml ethanol, evaporated under a
stream of nitrogen and redissolved in 210 μΐ of hexane/isopro-
panol (90 + 10 by vol) for HPLC. A Nucleosil 10-NO2 column
(16 χ 0.46 cm) was used for prepurification by HPLC. Gradient
elution was performed with two solvents, A and B. Solvent A
consisted of a mixture of n-hexane, isopropanol and water (2800
H- 1200 + 42 by vol). Solvent B was 7z-hexane. The flow was
4 ml per minute. From 0 — 5 minutes 13% A was used to elute
ealcidiol. From 5.0 — 5.5 minutes the percentage of A was in-
creased to 31%. At 10 minutes the flow through the column
was reversed and the percentage of A increased to 100%. After
9 minutes of backflushing the percentage of A was restored to
13% for reequilibration of the column for the next injection.
After 11 minutes of backflushing the flow direction was
switched back to normal. Total run time for each sample was
25 minutes. Calcidiol and calcitriol were collected from 2.0 —
2.6 minutes and 9.0-10.0 minutes, respectively. After evapo-
ration under nitrogen the fractions containing ealcidiol and
calcitriol were redissolved in 2000 and 175 μΐ, respectively, for
assessment of analytical recovery and final quantitation. In 5
series of assays (n = 199), part of the ealcidiol fraction was
used for the simultaneous quantitation of ealcidiol by HPLC
with UV detection at 254 nm and competitive protein binding
assay, in order to directly compare these two methods of quan-
titation. Within-run and between-run coefficients of variation
were determined by the inclusion of 4 control samples in each
series of assays.
Quantitation
The binding assays for ealcidiol and calcitriol were carried out
as described before (7). For quantitation of ealcidiol, 800 μΐ
were taken for the determination of analytical recovery, and
two 50 μΐ aliquots for competitive protein binding assay. The
remainder, approximately 1100 μΐ, was used for HPLC quan-
titation. After evaporation under nitrogen the residue was taken
up in 80 μΐ of methanol/water (88 + 12 by vol). Fifty μΐ were
injected onto a Nucleosil 5-C18 column (25 χ 0.46 cm). Meth-
anol/water (88 + 12 by vol) was used as the eluent at a flow
rate of 1.5 ml/min. The ealcidiol fraction was collected (ΙΟ-
Ι 3 minutes) and radioactivity was determined in 5ml of Per-
mafluor III after evaporation of the solvent. The sample con-
centration was calculated from peak height measurement and
the determined analytical recovery. Peak height was calibrated
each day by repeated injection of 30 ng of authentic ealcidiol
in 50 μΐ of solvent. A standard curve for caicidiol was con-
structed in the range of 12 to 120 ng of calcidibl.
Results
Analytical recoveries for caicidiol and calcitriol after
Sep-Pak CIS and straight phase HPLC purification
were 72% and 65% (n = 199), respectively. The re-
tention times of caicidiol and calcitriol on the Nu-
cleosil 10-NO2 column were 2.3 and 9.5 minutes re-
spectively. Ercalcidiol and caicidiol are not separated
on this column (7). The retention times were stable
for several months, which allowed reliable automatic
processing of several hundreds of sample extracts with
one column. The use of Sep-P k C18 cartridges re-
sulted in extracts which, after chromatqgraphy on the
Nucleosil 10-NO2 column, were clean enough to en-
able HPLC quantitation of caicidiol on the Nucleosil
5-C18 column. The peak height for caicidiol was linear
in the range from 12 to 120 ng (coefficient of corre-
lation r = 0.999). Figure 1 shows typical chrorhato-
grams of a standard solution and two human serum








Fig. 1. Representative UV tracings at 254 nm on a Nucleosil
5-C18 column (25 χ 4.6 mm; methanol/water (88 + 12
by vol) at a flow rate of 1.5 ml/min) of
1) 30 ng (0.075 nmol) of authentic caicidiol1,
2) a plasma extract of a sample containing 85 nmol/1 of
caicidiol after Sep-Pak C18 and HPLC prepurification,
and
3> plasma extract of a sample containing 27 nmol/1 of
caicidiol after Sep-Pak C18 and HPLC prepurification.
(10 nmol/1 equals 4 μg/l.) * *
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after Sep-Pak CIS and HPLC prepurification. There
was a good correlation between the competitive pro-
tein binding assay and the HPLC method for the
measurement of calcidiol (r: 0.987 ± 0.004; n = 5
series of assays). The average slope of the regression
line when HPLC values were plotted versus compet-
itive protein binding values was 1.14, with an average
intercept of 0.19 nmol/1. The mean within-run coef-
ficient of variation for calcidiol was 5% for the bind-
ing assay and 4% for the HPLC method. Between-
run coefficient of variation for calcidiol were 6% and
12% for the binding assay and the HPLC method,
respectively. Within-run and between-run coefficients
of variation for calcitriol in these 5 series were 6%
and 15%, respectively. The coefficients of variation
were determined at concentrations of approximately
50 nmol/1 and 100 pmol/1 for calcidiol and calcitriol,
respectively.
Discussion
At first we tested a previously described procedure
for the purification of calciol metabolites from plasma
(8). This method however, used only 2 ml of serum.
In our case, with sample volumes of 4 ml, substantial
amounts of radioactive spike were lost with the su-
pernatant of the sample extracts and during the wash-
ing procedure. The procedure was therefore modified
as described. Addition of 0.6 volume of water (2.5 ml
for a sample volume of 4ml) to the supernatant
prevented approximately 20% loss of radioactivity.
Washing with methanol/water (60 + 40 by vol) in-
stead of methanol/water (70 + 30 by vol) improved
recovery of radioactivity by a further 10%. Most of
these losses were probably calcitriol because this me-
tabolite elutes first from the Sep-Pak C18 cartridge.
Elütion with 2.5 ml ethanol resulted in complete re-
covery Of calcidiol and calcitriol from the cartridge.
The described HPLC gradient resulted in a sufficient
and fast isolation of calcidiol and calcitriol. To test
for the accumulation on the HPLC column of sub-
stances interfering with the binding assays (in the
absence of a back flush procedure), we analysed ten
control sera in one series omitting the back-flush
procedure and using only one Sep-Pak C18 cartridge.
No change in assay results was observed. However,
to exclude all possible interferences in the calcitriol
binding assay (9) during routine analysis of large
numbers of samples from patients with a wide variety
of metabolic disorders, we decided to maintain a ten
minute back flush procedure for routine purification.
The total HPLC run-time of 25 minutes allowed the
processing of 35—40 samples overnight. Since this is
close to the maximal number of samples that can be
handled in the binding assays, it was not necessary to
reduce the HPLC time further. The use of Sep-Pak
C18 cartridges and the Nucleosil 10-NO2 column for
prepurification enabled HPLC quantitation of calci-
diol without interference by endogenous UV-absorb-
ing contaminants. When only calcidiol concentrations
have to be determined or when information is required
about both calcidiol and ercalcidiol, the HPLC
method can be a valuable alternative to the compet-
itive protein binding method. The method differs from
the binding assay in that calcidiol and ercalcidiol are
separated in the described reversed phase system (8).
The binding assay measures the sum of calcidiol and
ercalcidiol. For clinical use the sum of calcidiol and
ercaleidiol is probably the best estimate of a person's
status. Significant amounts of ercalciol metabolites,
however, are usually not found in the Netherlands
and in Germany (9). In samples from 199 subjects,
we found no detectable quantity of ercalcidiol. This
is in contrast to the situation in the USA, Canada
and England, where a substantial proportion of the
samples contain ercalciol metabolites (3, 8, 10). Only
in cases of supplementation with ercalciol can one
expect a large contribution of ercalcidiol. Although
ercalcidiol concentrations can be estimated by assum-
ing the same analytical recovery for ercalcidiol and
calcidiol, we did not further evaluate the determina-
tion of ercalcidiol, because it is only very seldom
present in samples in the Netherlands. This was con-
firmed by the high correlation between the sum of
calcidiol and ercalcidiol concentrations, as determined
by the competitive protein binding method, and the
HPLC method measuring only calcidiol.
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